Stifel Financial
ABOS icon

Stifel Financial’s Acumen Pharmaceuticals ABOS Stock Holding History

Stifel Financial’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-13,650
Closed -$33K – 3366
2024
Q2 		$33K Sell
13,650
-1,000
-7% -$3.18K ﹤0.01% 3306
2024
Q1 		$59.3K Sell
14,650
-1,500
-9% -$5.65K ﹤0.01% 3248
2023
Q4 		$62K Buy
+16,150
New +$47.9K ﹤0.01% 3208

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Stifel Financial's ABOS Position: Q3 2024 in Review

Stifel Financial sold out of Acumen Pharmaceuticals (ABOS) in Q3 2024, closing a stake of 13,650 shares — an estimated $33K sold.

Stifel Financial first reported a position in ABOS in Q4 2023 and held it in 3 quarters. The position peaked at $62K in Q4 2023. 73 funds tracked by Wall St. Rank hold ABOS as of Q3 2024.

  • Stifel Financial reported no remaining Acumen Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Stifel Financial sold 13,650 Acumen Pharmaceuticals shares in Q3 2024, an estimated $33K.
  • Stifel Financial first reported a position in Acumen Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • Stifel Financial's Acumen Pharmaceuticals position peaked at $62K in Q4 2023.
  • 73 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q3 2024.

Based on Stifel Financial's 13F filing for Q3 2024, filed 14 Nov 2024.